 |
| |
| Aug-26-16 | Initiated |
Gabelli & Co |
Hold |
|
|
| Jun-29-16 | Initiated |
Bernstein |
Mkt Perform |
|
|
| Feb-25-16 | Initiated |
Citigroup |
Neutral |
$165 |
|
| Feb-08-16 | Reiterated |
Argus |
Buy |
$202 → $185 |
|
| Jan-20-16 | Initiated |
Credit Suisse |
Outperform |
$205 |
|
| Dec-15-15 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
| Dec-04-15 | Initiated |
Wells Fargo |
Market Perform |
|
|
| Oct-29-15 | Reiterated |
UBS |
Buy |
$168 → $180 |
|
| Sep-01-15 | Initiated |
Raymond James |
Mkt Perform |
|
|
| Jul-31-15 | Reiterated |
RBC Capital Mkts |
Outperform |
$185 → $190 |
|
| Jul-31-15 | Reiterated |
Deutsche Bank |
Buy |
$192 → $195 |
|
| Jul-31-15 | Reiterated |
Barclays |
Equal Weight |
$180 → $185 |
|
| May-28-15 | Reiterated |
Deutsche Bank |
Buy |
$200 → $192 |
|
| Apr-22-15 | Reiterated |
UBS |
Buy |
$175 → $185 |
|
| Apr-22-15 | Reiterated |
RBC Capital Mkts |
Outperform |
$178 → $185 |
|
| Oct-29-14 | Reiterated |
Argus |
Buy |
$140 → $185 |
|
| Oct-28-14 | Reiterated |
RBC Capital Mkts |
Outperform |
$150 → $165 |
|
| Sep-08-14 | Reiterated |
RBC Capital Mkts |
Outperform |
$138 → $150 |
|
| Aug-04-14 | Reiterated |
Argus |
Buy |
$135 → $140 |
|
| Jul-30-14 | Reiterated |
RBC Capital Mkts |
Outperform |
$125 → $138 |
|
|
|
| Sep-27-16 12:42PM | Why Wells Fargo, Gilead, Newfield, Amgen, and Chesapeake Energy Are Trending at Insider Monkey |
| 12:40PM | Stocks Extend Gains; Facebook Up On Positive Analyst Chatter |
| 11:54AM | Amgen's Multiple Myeloma Drug Bumbles Key Test Vs. Blockbuster Velcade |
| 11:38AM | Stocks Up After 1st Presidential Debate; Why Tesla Looks Healthiest In Weeks |
| 11:23AM | The Drug Price Increase Debate: Separating The Winners From The Losers |
| 11:15AM | Amgen (AMGN) Stock Slides, RBC: Clarion Trial May Have Failed Due to Design |
| 11:00AM | Amgen's multiple myeloma drug falls short in new-patient study Reuters |
| 10:44AM | Amgen: The Blame Game at Barrons.com |
| 10:12AM | Amgen/UCB's BLA for Osteoporosis Drug Accepted in the U.S. |
| 08:30AM | Amgen Inc Investor Conference Call to discuss CLARION Data scheduled for 8:30 am ET today |
| 08:23AM | Biosimilars in Limelight on FDA Approval of Amgen Drug |
| 07:50AM | Short Sellers Increase Bets in Major Biotechs at 24/7 Wall St. |
| 06:27AM | Amgen Multiple Myeloma Drug Kyprolis Fails to Help Newly Diagnosed Patients |
| 05:13AM | Amgen's multiple myeloma drug falls short in late stage study Reuters |
| 04:00AM | Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients PR Newswire |
| Sep-26-16 05:00PM | Amgen Opens Nomination Process For LabCentral Residency PR Newswire |
| 04:03PM | Wall Street Sells Off on Worries Over Clinton-Trump Showdown |
| 04:00PM | Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab PR Newswire |
| 02:38PM | Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies |
| 02:20PM | As Humira Alternative Gets FDA Approval, Is Abbvie in Trouble? |
| 01:53PM | Amgens Venture Funding Initiative (AMGN) at Investopedia |
| 10:05AM | And Then Theres Mylans Specialty Segment, Home of the EpiPen |
| 08:15AM | How Much Will Consumers Save on New Humira Biosimilar? at 24/7 Wall St. |
| 08:01AM | 3 Trades to Blaze a Trail Higher in Amgen |
| 06:49AM | Amgen's Biosimilar of Abbvie's Humira Gets FDA Approval |
| Sep-24-16 01:00AM | [$$] Biotech Is Cheaper Than Big Pharma at Barrons.com |
| Sep-23-16 07:42PM | FDA Approves Amgen's Biosimilar Version of Humira at The Wall Street Journal |
| 06:22PM | FDA approves lower-cost alternative to biotech drug Humira |
| 06:03PM | FDA Approves Amgen's AMJEVITA (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases PR Newswire |
| 05:50PM | U.S. FDA approves Amgen's copy of AbbVie arthritis drug Humira Reuters |
| 05:05PM | Will Amgen (AMGN) Stock Be Helped By FDA Approval of Humira Biosimilar? |
| 04:44PM | U.S. FDA approves Amgen's cheaper copy of arthritis drug Humira |
| 11:38AM | Top 5 profitable Biotech stocks : September 23, 2016 |
| 10:04AM | What Are Analysts Recommendations for Gilead Sciences? |
| 06:17AM | [$$] Biotech Is Cheaper Than Big Pharma: What to Buy at Barrons.com |
| Sep-22-16 07:00PM | Cramer Remix: Outrunning trading algorithms with the clic... |
| 09:56AM | New Setback for Sanofi's Lantus Increases Need for M&A |
| Sep-21-16 10:47AM | Amgen (AMGN) Repatha Meets Endpoints in Phase III Study |
| 10:05AM | Ionis, GlaxoSmithKline Partner on Abnormal Protein Treatment |
| Sep-20-16 03:24PM | Romosozumab From Amgen Inc (AMGN) Shows Positive Results In Osteoporosis at Insider Monkey |
| 12:09PM | The 5 Top-Selling Drugs In The World |
| 11:04AM | Teva, Eli Lilly Have Migraine Treatments in Trial Phases |
| 10:05AM | Alder BioPharmaceuticalss Migraine Therapy Shows Promise |
| 09:00AM | Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab) PR Newswire |
| 08:05AM | Entering Migraine Market Wont Be Easy for Novartis, Amgen |
| Sep-19-16 01:06PM | Amgen-Servier Collaboration Commercializes Chronic Heart Therapy Globally (AMGN) at Investopedia |
| 11:30AM | Amgen Inc Conference Call to Discuss the results from the romosozumab phase 3 postmenopausal osteoporosis study scheduled for 11:30 am ET today |
| 11:07AM | Amgen Products Threatened by Court Losses (AMGN) at Investopedia |
| 10:38AM | Amgen (AMGN) Parsabiv Gets Positive CHMP Opinion in EU |
| 08:25AM | RBC Says These 4 Top Biotechs Could Have Big Upside Potential at 24/7 Wall St. |
| Sep-18-16 11:00AM | Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis PR Newswire |
| Sep-17-16 02:06PM | Technical Analysis of Markets 9/16/16 |
| 11:41AM | Is This New Market the Biggest Investment Idea of the Decade? at Motley Fool |
| 10:00AM | AMGN: How Amgen's Stock Price Rose 18.55% in 6 Months at Investopedia |
| Sep-16-16 05:41PM | [$$] Abingworth Seeds Immunotherapy Startup GammaDelta at The Wall Street Journal |
| 03:54PM | Amgen Targeting Biosimilars (AMGN) at Investopedia |
| 12:09PM | Novartis says experimental drug helps chronic migraine sufferers |
| 07:33AM | Amgen Receives Positive CHMP Opinion For Parsabiv (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adult Patients With Chronic Kidney Disease On Hemodialysis PR Newswire |
| 06:54AM | Dr. Reddys Expands Strategic Collaboration with Amgen in India Business Wire |
| Sep-15-16 04:30PM | Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine PR Newswire |
| Sep-14-16 06:40PM | Third Avenue Fund Comments on Amgen |
| 04:00PM | Amgen To Webcast Investor Call PR Newswire |
| 01:15PM | Third Avenue Value Fund 3rd Quarter Letter |
| 12:29PM | Amgen, Inc. Value Analysis (NASDAQ:AMGN) : September 14, 2016 |
| 12:00PM | Amgen (AMGN) Stock Is Wednesday's 'Chart of the Day' |
| 08:17AM | AbbVie's Battle Royale |
| Sep-13-16 09:57PM | [$$] Takeda earmarks $15bn for US pharma acquisitions at Financial Times |
| 04:00PM | Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference PR Newswire |
| 01:20PM | Big Pharma Spends Millions to Keep Prices High for California Agencies |
| 10:04AM | Biogen Committed to Bolstering Its Strong Product Pipeline |
| 09:30AM | The Zacks Analyst Blog Highlights: Spectrum Pharmaceuticals, Amgen, AbbVie and Vertex Pharmaceuticals |
| 08:04AM | Product Launches Are Part of Biogens Plans to Boost Revenues |
| 08:04AM | Amgen, Inc. breached its 50 day moving average in a Bullish Manner : AMGN-US : September 13, 2016 |
| 07:05AM | Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St. |
| 12:10AM | [$$] On Bank of Englands Shopping List: Apple, Daimler Bonds at The Wall Street Journal |
| Sep-12-16 06:45PM | Traders pick biotech stocks as sector sees best day in months at CNBC |
| 05:00PM | Buying biotech: 5 trades in pharma |
| 04:12PM | [$$] On Bank of England's Shopping List: Apple, Daimler Bonds at The Wall Street Journal |
| 03:32PM | Biotech: Four Catalysts for Four Stocks at Barrons.com |
| 11:59AM | Two Things You Must Understand About Biotech Investing at Motley Fool |
| 10:27AM | ETFs with exposure to Amgen, Inc. : September 12, 2016 |
| 09:23AM | 3 Drug Stocks That Could Benefit from Key FDA Events in Sep 2016 |
| Sep-11-16 08:00PM | Charts Show Something Broke Friday |
| 07:36AM | Fed Members Should Talk Less, Guide Better and Think Globally |
| Sep-09-16 03:04PM | Market Watches to See if Biogen Will Meet Its Raised Guidance |
| 02:03PM | Here's When You Should Buy Amgen |
| 11:04AM | Analysts Look for Celgene to Offer Striking Returns in 2016 |
| Sep-08-16 04:00PM | Amgen To Present At The Morgan Stanley Global Healthcare Conference PR Newswire |
| 11:29AM | Merck's Lung Cancer Drug Keytruda Under Priority Review |
| 11:04AM | Celgene Carves Out More Share of This Cancer Treatment Market |
| 10:04AM | What Are the Possible Threats to Revlimid? |
| 08:08AM | 3 Attractive Income Stocks Whose Dividends Could Double at Motley Fool |
| Sep-07-16 04:13PM | Goldman's 7 Favorite Biotech Ideas For 2016 |
| 04:00PM | Amgen to Highlight 19 Abstracts on Osteoporosis Disease State and Treatment at American Society for Bone and Mineral Research Annual Meeting PR Newswire |
| 02:04PM | Celgenes Enterprise Value to Earnings in Line with Peers |
| 11:41AM | Understanding Celgenes Premium PE Valuation |
| 09:30AM | Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled |
| Sep-06-16 09:00AM | Syngene International Commissions Dedicated R&D Center for Amgen Business Wire |
| 08:15AM | A $14,000 Price Tag For A Cholesterol Drug Can Be A Bargain at Forbes |
| 07:55AM | Amgen Has Many Ways to Win |
|
|
|
|
| Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its principal products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of high cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc.; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc.; Advaxis, Inc.; and Dr. Reddy's Laboratories Ltd. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| de Carbonnel Francois | Director | Sep 09 | Option Exercise | 71.64 | 5,000 | 358,200 | 21,171 | Sep 13 06:21 PM | | Such Annette Louise | VP, Finance and CAO | Aug 02 | Sale | 174.59 | 3,000 | 523,758 | 7,183 | Aug 03 08:14 PM | | Balachandran Madhavan | EVP, Operations | May 04 | Sale | 154.12 | 30,000 | 4,623,624 | 55,996 | May 05 08:16 PM | | BALTIMORE DAVID | Director | Apr 29 | Sale | 157.21 | 3,312 | 520,684 | 32,350 | May 03 07:12 PM | | BALTIMORE DAVID | Director | Mar 30 | Option Exercise | 50.44 | 5,000 | 252,200 | 37,350 | Mar 31 06:01 PM | | HERRINGER FRANK C | Director | Mar 14 | Option Exercise | 50.44 | 5,000 | 252,200 | 30,608 | Mar 16 06:48 PM | | COFFMAN VANCE D | Director | Mar 09 | Option Exercise | 50.44 | 5,000 | 252,200 | 43,447 | Mar 10 06:55 PM | | Bradway Robert A | Chairman, CEO and President | Mar 02 | Option Exercise | 50.44 | 84,000 | 4,236,960 | 447,102 | Mar 04 06:07 PM | | Bradway Robert A | Chairman, CEO and President | Mar 02 | Sale | 146.48 | 20,000 | 2,929,566 | 383,102 | Mar 04 06:07 PM |
|
|
|
|
|
|
